News

CORT 108297 is the lead compound from our three series of proprietary selective GR-II antagonists and is a fused-ring azadecalin. This series of compounds has demonstrated a greater

The study, conducted at Jolimont Hospital in Haine Saint Paul, Belgium, prospectively evaluated MTWA in 73 consecutive patients who met criteria for implantable cardioverter defibrillator implantation for primary

The goal of the ACRG is to improve the knowledge of cancers prevalent in Asia and to accelerate drug discovery efforts by freely sharing the resulting data with

NanoGuardian’s NanoEncryption technology works directly on capsules, tablets, vial caps, and single-use syringes to provide a layered security strategy consisting of overt, covert and forensic security features. NanoGuardian

Reportedly, Dishman had invested around $10m in the Shanghai facility that expands over 40,000sqmt at the Shanghai Chemical Industry Park. The facility will make quaternary salts and intermediates

Merck KGaA reported that the cost of sales grew faster than sales due to underutilisation of capacities, mainly in the chemicals business sector. Therefore, the Group gross margin

The re-examination filing provides evidence from the Phase III trial (Study 904) in relation to possible bias in the decision to re-intervene, and the validity of the endpoint.

The contract modification, which is effective February 22, 2010 and extends until December 31, 2012, provides for up to $61m during a ‘base period’ of performance with options

As per the agreement ART has granted Nihon a non-exclusive and restricted right and license to use, sell and sub-license its proprietary signal-averaging electrocardiography (SAECG) software, Predictor, customised